SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Creative Media & Community Trust Corp. is a real estate investment trust that seeks to own, operate, and develop premier multifamily and creative office assets in vibrant and emerging communities throughout the United States. It operates through the following segments: Office, Hotel, and Lending. The Office segment consists of the rental of office space and other tenant services, including tenant reimbursements, parking, and storage space rental. The Hotel segment involves the operation of hotel properties. The Lending segment focuses on loans to small businesses. The company was founded in 1993 and is headquartered in Dallas, TX.

Creative Media & Community Trust

CMCT is trending due to significant momentum and volume, leading to a breakout and potential short squeeze. Community members are actively discussing profit-taking strategies, with some suggesting the stock could become the next low-float runner. The stock's low float and potential for a squeeze are major talking points.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Conversations around DJT are heavily focused on political affiliations following a shooting involving Charlie Kirk, with community members debating the shooter's motives and ideological alignment. Some users are pointing fingers between the left and right, while others are highlighting the broader implications of political rhetoric and violence. The stock is also being discussed in relation to broader market trends and potential financial impacts.

Asset Entities, Inc. engages in providing social media marketing and content delivery services. It offers its services to Discord, TikTok, and other social media platforms. It also designs, develops and manages servers for communities on Discord. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani and Kyle Fairbanks on August 1, 2020 and is headquartered in Dallas, TX.

Asset Entities Inc - Ordinary Shares - Class B

Asset Entities Inc.

Asset Entities is trending as the community anticipates a potential short squeeze following the completion of its merger with Strive Enterprises; traders are closely watching for a CUSIP change and its potential impact on short positions. Chatter revolves around the possibility of the company investing its substantial treasury into Bitcoin, drawing comparisons to other companies in the crypto space. Some traders express frustration that the price has not yet reflected the merger news and the potential for a short squeeze.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP.X is trending as the community speculates on potential catalysts, including a possible spot ETF and upcoming rate cuts, while also closely monitoring price action and key resistance levels. Discussions include both bullish sentiment, with some anticipating a significant breakout, and skepticism regarding its performance compared to other cryptocurrencies. Traders are actively debating strategies around accumulating and holding versus taking profits.

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Atyr Pharma Inc

aTyr Pharma, Inc

ATYR is trending as traders anticipate Phase 3 data, expected mid-September, with the community actively debating potential outcomes and price targets. Bullish sentiment is fueled by recent institutional buying and analyst ratings, while bears cite concerns over trial design and past performance, with some highlighting the involvement of controversial figures known for short selling. The potential for a short squeeze and the high implied volatility are adding to the speculative buzz.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is trending downwards as reports circulate that the Trump administration may link COVID-19 vaccines to child deaths, creating uncertainty around the stock's future. The community is discussing the potential impact of this news, while some investors see a buying opportunity due to the perceived overreaction and low valuation. Discussions also include Moderna's pipeline beyond COVID-19, especially its personalized cancer vaccine program.

Gemini Space Station Inc. - Ordinary Shares- Class A

Gemini Space Station

Gemini Space Station ($GEMI) is trending after its IPO, with the community actively discussing its potential and comparing it to other recent IPOs. Some investors are excited about the company's prospects and credit card rewards program, while others express concerns about its valuation and potential for a pullback. The stock's initial trading volatility and comparison to other crypto-related companies are also key talking points.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer is trending amid discussions around the implications of potential shifts in government policy regarding COVID-19 vaccines, including concerns about linking vaccines to child deaths. The community is weighing the potential impact on Pfizer's revenue and future prospects, with some questioning liability and others pointing to the company's broader pipeline beyond vaccines. Additionally, some traders are closely monitoring technical indicators and dividend payouts, viewing the dip as a possible buying opportunity.

GlucoTrack, Inc. designs, develops, and commercializes non-invasive glucose monitoring devices for use by persons suffering from diabetes. The company offers the GlucoTrack model DF-F glucose monitoring device, which utilizes a patented combination of ultrasound, electromagnetic and thermal technologies to obtain glucose measurements in less than one minute via a small sensor that is clipped onto one's earlobe and connected to a small, handheld control and display unit, all without drawing blood or interstitial fluid. It was designed to help people with diabetes and pre-diabetics obtain glucose level readings without the pain. The company was founded by Avner Gal and David Malka in September 2001 and is headquartered in Rutherford, NJ.

GlucoTrack Inc

GCTK is trending due to a recently announced $20 million investment agreement, sparking significant price movement and active discussion about its potential. The community is focused on the stock's low float and speculating about a potential short squeeze, while also keeping an eye on an upcoming investor summit. Some traders are also wary of dilution and high volatility.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

$BROKE.X is trending due to the excitement surrounding its upcoming listing on BiFinance and a live 'Biggest Buy Contest', which the community sees as key catalysts. The community emphasizes that the project is built on organic growth and hard work, not hype, and they are rallying together to push the coin to new all-time highs. Many community members express strong conviction and encourage others to DYOR and join their Telegram group to learn more.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

IONS Up on FDA's Breakthrough Tag for ION582 in Angelman Syndrome

Ionis jumps as FDA grants Breakthrough Therapy status to ION582 for treating Angelman syndrome, with the phase III study now underway.

IONS Hits 52-Week High on Tryngolza's Success in Lowering Triglyceride

Ionis surges to a 52-week high after Tryngolza shows strong triglyceride reductions and cuts acute pancreatitis risk by 85% in late-stage studies.

Ionis Pharmaceuticals, Inc. (IONS) announced on Tuesday that its medicine, Olezarsen, reduced triglycerides and acute pancreatitis events in late-stage trials evaluating the drug in individuals with severe hypertriglyceridemia.Severe hypertriglyceridemia (sHTG) is defined by severely high triglycerides reaching into the thousands. It is characterized by an increased risk of acute pancreatitis and other morbidities. According to Ionis, approximately three million people are living with sHTG in the U.S., including more than one million who are considered high risk.In two <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.ionis.com/news-releases/news-release-details/olezarsen-significantly-reduces-triglycerides-and-acute">studies</a>, Olezarsen demonstrated a highly statistically significant placebo-adjusted mean reduction in fasting triglycerides of up to 72% at six months, as well as a highly statistically significant 85% reduction in acute pancreatitis events, with favorable safety and tolerability profiles. The two trials cumulatively enrolled nearly 1,100 patients who were required to be on standard-of-care lipid-lowering therapy throughout the treatment period.<a href="https://stocktwits.com/symbol/IONS">IONS stock</a> rocketed by 34% by Tuesday afternoon, reaching its February 2021 highs. On Stocktwits, retail sentiment around IONS jumped from ‘bearish’ to ‘extremely bullish’ over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:624/59;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_02_at_2_02_09_PM_png_166853294f.webp" alt="IONS's Sentiment Meter and Message Volume as of 2:02 p.m. ET on Sept. 2, 2025 | Source: Stocktwits" width="624" height="59"><figcaption>IONS's Sentiment Meter and Message Volume as of 2:02 p.m. ET on Sept. 2, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed optimism about the company’s future.<stembedurl>https://stocktwits.com/Mookins/message/627214651</stembedurl>Sam Tsimikas, senior vice president of global cardiovascular development at Ionis, termed the data “groundbreaking” and noted that the data reinforce the company’s confidence that the medicine has the potential to change how sHTG is treated. According to the firm, current standard of care therapies for sHTG and lifestyle modifications do not sufficiently or consistently lower triglyceride levels or reduce the risks of sHTG in all patients.Ionis plans to submit a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration for approval of Olezarsen in sHTG by the end of the year. The drug is already approved in the U.S. as Tryngolza as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia (FCS).Several analysts hiked their price target on the stock following the news:<ul style="list-style-type:square;"><li>H.C. Wainwright raised its price target to $95 from $70 while keeping a ‘Buy’ rating on the shares. The firm also hiked its forecast for global Olezarsen sales up to $4.2 billion from $3.2 billion.</li><li>Jefferies raised its price target to $96 from $83 and kept a ‘Buy’ rating on the shares. The firm increased its estimate of Olezarsen's peak sales to about $2.5 billion from $1.5 billion due to higher assumed penetration in sHTG.&nbsp;</li><li>Barclays raised its target to $78 from $58, while keeping an ‘Overweight’ rating on the shares.</li><li>Morgan Stanley raised its price target to $71 from $62 and kept an ‘Overweight’ rating on the shares.</li></ul>IONS' stock is up 64% this year and approximately 21% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/nio-expects-sales-bump-for-remainder-of-year-after-new-models-bring-strong-demand/chv6z3WRdFg">Nio Expects Sales Bump For Remainder Of Year After New Models Bring In Strong Demand: Retail Sees Stock Hitting At Least $10 By Year-End</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Ionis Pharmaceuticals logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

IONS Stock Soars 34% To Hit February 2021 Highs After Medicine Shows Positive Effect On Elevated Triglyceride Levels In Late-Stage Studies 

In two studies, Ionis’ Olezarsen demonstrated a highly statistically significant placebo-adjusted mean reduction in fasting triglycerides of up to 72% at six months. 

Equity

In two studies, Ionis’ Olezarsen demonstrated a highly statistically significant placebo-adjusted mean reduction in fasting triglycerides of up to 72% at six months. 


Wall Street analysts boosted their targets on Ionis Pharmaceuticals after the FDA approved its RNA-based drug Dawnzera for hereditary angioedema, sparking a surge in retail chatter.&nbsp;BofA Securities raised its price target to $64 from $63 while maintaining a ‘Buy’ rating, saying Dawnzera’s approval was on time with a clean label that allows dosing every four or eight weeks and carries no major safety warnings, as per The Fly.Analyst Jason Gerberry said the firm’s decision to un-risk-adjust Dawnzera forecasts in its model supported the upward revision.Stifel also lifted its target to $43 from $38 but kept a ‘Hold’ rating, calling the approval “clean” and in line with other HAE labels.&nbsp;The firm said Ionis management is confident patients will continue switching from existing options due to unmet needs, describing Dawnzera as offering a compelling product profile.The FDA approval marked a milestone for Ionis, making Dawnzera the first and only RNA-targeted prophylactic treatment for HAE.&nbsp;The decision was based on results from the Phase 3 OASIS-HAE study, where the drug reduced monthly attack rates by 81% compared to placebo over 24 weeks. Longer-term data showed sustained reductions of more than 90% and strong patient preference in switch studies versus existing prophylactic therapies.HAE is a rare, potentially life-threatening condition marked by recurrent swelling attacks that affect about 7,000 people in the U.S.&nbsp;Dawnzera, which targets plasma prekallikrein, will be available in the U.S. in the coming days and can be self-administered via autoinjector once every four or eight weeks.Ionis CEO Brett Monia said the approval represents a “significant advance” for patients and marks the company’s second independent drug launch in nine months, following the approval of Tryngolza for familial chylomicronemia syndrome.On Stocktwits, retail sentiment for Ionis was ‘extremely bullish’ amid ‘extremely high’ message volume.One user said Ionis may not see much more upside from the FDA approval of Dawnzera, noting that “the next earnings will be the real mover” since the approval was already priced in.<stembedurl>https://stocktwits.com/moses_ametuer/message/626141804</stembedurl>Another user compared Ionis to other biotech names, pointing out they had a similar experience with Precigen and Tonix Pharmaceuticals last week. Both received FDA approvals but saw sharply different stock reactions, with Precigen rallying 75% after its trading halt while Tonix fell 15%.&nbsp;The trader added they were hoping for a good run with Ionis.<stembedurl>https://stocktwits.com/jvbiotek/message/626111256</stembedurl><a href="https://stocktwits.com/symbol/IONS">Ionis’ stock</a> has risen 23.7% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Retail Traders Pile Into Ionis As Wall Street Hikes Price Targets On FDA Approval Of Swelling Disorder Therapy

BofA Securities raised its target to $64 with a ‘Buy’ rating, while Stifel lifted its target to $43 with a ‘Hold,’ both citing Dawnzera’s clean label and flexible dosing.

BioCryst Pharmaceuticals Before Q2 Earnings: How to Play the Stock

BCRX gears up for Q2 results with Orladeyo growth in focus, but 2025 EPS forecasts dip as investors eye pipeline progress.

Here's What Key Metrics Tell Us About Ionis Pharmaceuticals (IONS) Q2 Earnings

While the top- and bottom-line numbers for Ionis Pharmaceuticals (IONS) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Ionis Pharmaceuticals (IONS) Q2 Earnings and Revenues Beat Estimates

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of +218.52% and +66.96%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Ionis Pharmaceuticals (IONS) Earnings Expected to Grow: Should You Buy?

Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ionis Pharmaceuticals founder Stanley Crooke on the fight against rare diseases

Stanley Crooke, Ionis Pharmaceuticals founder and n-Lorem founder, joins 'Squawk Box' to discuss the fight against rare diseases, the development of ASO technology, and more...

Should You Buy Ionis Pharmaceuticals (IONS) After Golden Cross?

Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia on January 10, 1989 and is headquartered in Carlsbad, CA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$1.22	--	--	N/A
Q2 '25	-$0.09	$0.70	868.38%	BEAT
Q1 '25	-$1.10	-$0.93	15.28%	BEAT
Q4 '24	-$1.12	-$0.66	40.85%	BEAT
Q3 '24	-$1.12	-$0.95	15.48%	BEAT

IONS
Ionis Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest IONS News

IONS Ionis Pharmaceuticals Inc